SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Intelligent Bio Solutions, Inc. is a medical technology company, which engages in delivering testing solutions. It operates through the Intelligent Fingerprinting Products (IFPG) and Saliva Glucose Biosensor Platform (SGBP) segments. It offers biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was founded on December 5, 2016 and is headquartered in New York, NY.

Intelligent Bio Solutions Inc

Intelligent Bio Solutions is trending due to a strategic manufacturing partnership with Syrma Johari MedTech, which aims to scale production of its fingerprinting drug screening reader and anticipates substantial cost savings. This positive news, however, is being overshadowed by a significant private placement and share offering that has fueled community concerns over potential dilution. Traders are actively debating the impact of this offering on the stock's recent volatility and future price trajectory.

Litecoin is a peer-to-peer cryptocurrency created by Charlie Lee. It was created based on the Bitcoin protocol but differs in terms of the hashing algorithm used. Litecoin uses the memory intensive Scrypt proof of work mining algorithm. Scrypt allows consumer-grade hardware such as GPU to mine those coins.  Why Litecoin? Litecoin is a cryptocurrency that has evolved from Bitcoin after its own popularity in the industry, this alternative, or ‘altcoin’ has emerged to allow investors to diversify their digital currency package, according to Investopedia. Litecoin is one of the most prominent altcoins and was created by former Google employee and Director of Engineering at Coinbase, Charlie Lee. Litecoin was the first to alter Bitcoin and the most significant difference is that it takes 2.5 minutes for Litecoin to generate a block, or transaction, in comparison to Bitcoin's 10 minutes.  ‘While this matters little to traders, miners who use hardware to run Bitcoin's network cannot switch over to Litecoin. This keeps bigger mining conglomerates away from Litecoin because they cannot easily optimize their profits by swapping to another coin, contributing to a more decentralized experience. Litecoin also has bigger blocks, and more coins in circulation, making it more affordable and swift when transacting,’ Investopedia explained.  As explained above, Litecoin can transact a lot faster than Bitcoin, but there are also a number of other characteristics that investors need to know before trading. Litecoin can handle higher volumes of transactions because of the capability of transacting faster and if Bitcoin attempted to transact on the scale of its altcoin, a code update would be needed. However, Litecoin’s blocks would be larger, but with more ‘orphaned blocks'. The faster block time of litecoin reduces the risk of double spending attacks - this is theoretical in the case of both networks having the same hashing power.  Litecoin Technical Details: The transaction confirmation time taken for Litecoin is about 2.5 minutes on average (as compared to Bitcoin's 10 minutes). The Litecoin network is scheduled to cap at 84 million currency units.   Litecoin has inspired many other popular alternative currencies (eg. Dogecoin) because of its Scrypt hashing algorithm in order to prevent ASIC miners from mining those coins. However it is said that by the end of this year, Scrypt ASIC will enter the mass market.

Litecoin

Litecoin is actively trending as its community eagerly anticipates the start of a new yearly cycle, with many predicting a significant bullish reversal based on historical performance. Investors are discussing aggressive accumulation, forecasting substantial long-term growth and positioning LTC as a strong contender for major appreciation in upcoming crypto market upturns.

Sensei Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company which focuses on the discovery, development, and delivery of next generation immunotherapies for the treatment of cancer and infectious diseases. The company was founded in 1999 and is headquartered in Rockville, MD.

Sensei Biotherapeutics Inc

Sensei Biotherapeutics (SNSE) is experiencing significant momentum driven by its extremely low share float, fueling widespread community discussion around its potential for a short squeeze. Traders are actively accumulating shares, anticipating a parabolic breakout and new highs as volume continues to build, drawing comparisons to other recent volatile low-float stocks.

ESH Acquisition Corp. is a blank check company. It was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was founded on November 17, 2021 and is headquartered in New York, NY.

ESH Acquisition Corp - Ordinary Shares - Class A

ESHA is trending as a low-float SPAC, sparking widespread community discussion about its potential for explosive upward movement. Traders are actively debating whether it will follow the recent parabolic runs seen in similar micro-float companies, with many advocating for holding positions amid high volatility. The conversation emphasizes the stock's thin order book and the perceived impact of high insider ownership on its price action.

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Axsome Therapeutics Inc

Axsome Therapeutics is trending upward following significant regulatory updates, including the FDA's priority review of AXS-05 for Alzheimer's disease agitation and positive feedback supporting an NDA submission for AXS-12 in narcolepsy. The community is buzzing with excitement, celebrating these milestones as pivotal catalysts that could drive substantial market expansion and propel the company toward future growth, particularly given the high impact of Alzheimer's-related treatments.

Alchemy Investments Acquisition Corp. 1 is a blank check company, which engages in merger, share exchange, asset acquisition, share purchase, and reorganization or similar business combination. The company was founded on October 27, 2021 and is headquartered in Newark, DE.

Alchemy Investments Acquisition Corp 1 - Ordinary Shares - Class A

Alchemy Investments Acquisition Corp 1 (ALCY) is actively trending as the community speculates it could be the next low-float SPAC to experience a substantial price surge, drawing parallels to recent strong performers like ESHA. Traders are enthusiastically discussing a potential significant move, driven by the broader "low float SPAC bubble" theme and the perceived ease of high-percentage gains. This collective anticipation is fueling positioning and elevated trading activity.

Aquestive Therapeutics, Inc. engages in the identifying, developing, and commercializing differentiated products to address unmet medical needs and to solve patients’ therapeutic problems. Its product pipeline include Libervant, AQST-108, AQST-305, Suboxone and Zuplenz. The company was founded in January 2004 and is headquartered in Warren, NJ.

Aquestive Therapeutics Inc

Aquestive Therapeutics is trending with high anticipation ahead of Anaphylm's pivotal FDA decision on January 31, 2026, for its novel, device-free epinephrine film. Community discussion is vibrant, with many confident in approval citing strong clinical data and a waived advisory committee, while others express caution due to historical regulatory setbacks and a notable short interest. The market keenly watches if Anaphylm will significantly disrupt the existing anaphylaxis treatment landscape, challenging rivals like SPRY.

BigBear.ai Holdings, Inc. engages in data-driven decision dominance and advanced analytics that provide its customers with a competitive advantage in a world driven by data that is growing in terms of volume, variety, and velocity. The firm operationalizes artificial intelligence and machine learning at scale through its end-to-end data analytics platform. It deploys its observe, orient and dominate products to customers throughout the defense, intelligence, and commercial markets. The company was founded in 2020 and is headquartered in McLean, VA.

BigBear.ai Holdings Inc

BigBear.ai (BBAI) is actively trending following the announced completion of its Ask Sage acquisition, a strategic move aimed at enhancing its secure generative AI capabilities for government and regulated industries. This development is sparking community discussion around its potential to secure significant government contracts, particularly for defense and airport security, amidst ongoing debates regarding upcoming shareholder votes on dilution and the stock's future trajectory within the AI-driven government tech sector.

DoubleZero is a high-performance global network of independently contributed links, purpose-built for blockchain and other distributed systems. It provides direct, low-latency routing that strengthens validator performance and supports faster, fairer participation worldwide.  2Z Tokens are used to access the network’s connectivity service, and, on the other side, reward network contributors and resource providers based on performance and reliability. 2Z Tokens can also be staked to enhance the security of the network.

DoubleZero

DoubleZero ($2Z) is trending amidst buzz regarding new listings on major crypto exchanges, which is fueling significant trading volume. The community is actively discussing its fiber optics technology, anticipating substantial altseason gains, though some express caution regarding its rapid volatility.

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. The company has three commercial products: Gvoke, Keveyis, and Recorlev. Gvoke is ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. Its product also includes Ogluo which is used for the treatment of severe hypoglycemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Xeris Biopharma Holdings Inc

Xeris Biopharma is trending after a competitor's drug for Cushing's syndrome faced an FDA rejection, providing a clearer path for Xeris's approved treatment, Recorlev. The community is actively discussing why the positive competitive development for Xeris hasn't yet led to a more substantial price movement. Analysts generally view this as a significant tailwind for Recorlev to expand its market share within the growing Cushing's syndrome market.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of Swiss pharmaceutical giant Novartis AG were flat on Friday morning in heavy trading volume, despite the company reporting impressive quarterly results.&nbsp;Novartis posted core fourth-quarter (Q4) earnings per share (EPS) of $1.98, up from $1.53 last year, beating the consensus estimate of $1.80.&nbsp;Meanwhile, Q4 revenue reached $13.2 billion, surpassing the previous year’s $11.4 billion and analysts’ expectations of $12.84 billion.The company attributed its strong sales growth to its blockbuster heart-failure drug Entresto and arthritis medication Cosentyx.&nbsp;CEO Vas Narasimhan expressed optimism, stating, “In our first full year as a pure-play innovative medicines company, Novartis delivered one of the strongest financial performances in our history, growing sales 12% cc [constant currency basis] and core operating income 22% cc.”&nbsp;He added that the company achieved key innovation milestones, including new drug approvals and promising data that would drive growth in the mid- to long-term.Despite the upbeat results, retail sentiment on Stocktwits was mixed. Although message volume surged into ‘extremely bullish’ territory, sentiment remained ‘bearish,’ indicating some hesitation among retail traders.&nbsp;<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/NVS_sentiment_and_message_volume_Jan_31_d92ad15174.png" alt="NVS sentiment and message volume Jan 31.png" width="1318" height="324"><figcaption>NVS sentiment and message volume Jan 31 as of 11:45 am ET | source: Stocktwits</figcaption></figure>Novartis is facing upcoming patent expirations for three key drugs, with Entresto expected to face generic competition in the U.S. mid-year.&nbsp;Additionally, two other top-selling drugs, Tasigna for leukemia and Promacta for a blood disorder, will face generics in the U.S.However, Narasimhan reassured investors, emphasizing the company’s “tremendous replacement power” and its ability to bring new treatments to market when patents on existing drugs expire.&nbsp;He also highlighted the company’s strong pipeline, with more than 30 assets that could drive differentiated growth over the long term, including updates on its cardiovascular drug candidate pelacarsen and a key late-stage trial this year.Looking ahead, Novartis forecasted FY25 net sales growth in the mid- to high-single-digit range, with core operating income expected to grow in the high single to low double-digit range.&nbsp;The company also proposed a 6.1% increase in its dividend to 3.50 Swiss francs per share for 2024.Although <a href="https://stocktwits.com/symbol/NVS">Novartis' stock</a> has lost 0.1% over the past 12 months, it is up more than 7% so far this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Novartis company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Novartis Gets Retail Chatting After Upbeat Q4, But Sentiment Stays Tepid Amid Volatile Trading

The company is facing upcoming patent expirations for three key drugs, with Entresto expected to face generic competition in the U.S. mid-year. 

Equity

The company is facing upcoming patent expirations for three key drugs, with Entresto expected to face generic competition in the U.S. mid-year. 


U.S. shares of Sony Group Corp. (<a class="mention" data-mention="$SONY" data-symbol-id="SONY" href="https://stocktwits.com/symbol/SONY" target="_blank">$SONY</a>) surged over 7% pre-market Friday after the company reported a 69% jump in fiscal&nbsp;second-quarter (Q2) profit, driven by strength in its gaming and imaging divisions.&nbsp;Sony posted a profit of 338.5 billion yen (about $2.21 billion) on revenue of 2.91 trillion yen, up 3% year-over-year.&nbsp;The&nbsp;earnings per share (EPS) of 55.86 yen beat the consensus estimate of 39.84 yen, according to FactSet.The company saw robust performance in its Game &amp; Network Services and Imaging &amp; Sensing Solutions segments.&nbsp;Operating profit for the imaging business nearly doubled to 92.41 billion yen due to strong demand for image sensors, though Sony lowered its full-year sales and profit outlook for this segment.&nbsp;Despite selling only 3.8 million PlayStation 5 units this quarter — down from 4.9 million a year ago — Sony raised its annual profit forecast for the game division to 355.0 billion yen from 320.0 billion yen.Sony also launched its upgraded PlayStation 5 Pro this week, ahead of the holiday season, offering enhanced performance over the original 2020 model.&nbsp;The company revised its revenue forecast for the fiscal year ending March 2025, now expecting a 2.4% decline to 12.71 trillion yen, slightly better than the previously forecasted 3.2% drop.&nbsp;However, it maintained its outlook for a modest 1% increase in net profit to 980.0 billion yen.On Stocktwits, Sony was one of the top 30 trending tickers as of 7:30 am ET, reflecting heightened retail interest.&nbsp;<stembedurl>https://stocktwits.com/DT777/message/591690734</stembedurl>Still, Sony’s U.S.-listed shares are down over 2% year-to-date. Meanwhile, Tokyo-listed shares of the firm ended 1.2% higher on Friday.For updates and corrections, email&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="mailto:newsroom@stocktwits.com">newsroom@stocktwits.com</a>Read next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/usm-tds-stocks-get-upgraded-by-raymond-james/cJ45RFrRaJ">Are USM, TDS Trump Trades Now? Raymond James Upgrades Mid-Cap Telecom Stocks On Reduced Regulatory Risk</a>

Sony also launched its upgraded PlayStation 5 Pro this week, ahead of the holiday season.

Sony Stock Jumps Pre-Market As Profit Booms Nearly 70%: Retail Buzz Builds

Despite selling only 3.8 million PlayStation 5 units this quarter — down from 4.9 million a year ago — Sony raised its annual profit forecast.

AVIV
American Century ETF Trust - Avantis International Large Cap Value ETF

Feed

News

Sentiment

Fundamentals

Info

Latest AVIV News

AVIVAmerican Century ETF Trust - Avantis International Large Cap Value ETF